LAZATATUG
UNII 2D37ZW7U9U

Substance Identification & Data

This profile provides standardized clinical and technical data for Lazatatug, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 2D37ZW7U9U.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3035565-36-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

2D37ZW7U9U

CAS Registry Number

3035565-36-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LAZATATUG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C224753

National Cancer Institute reference terminology for clinical and research data.

INN ID

13736

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lazatatug. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LAZATATUG

Common Names & Synonyms

H-EPSILON HEAVY CHAIN CHIMERIC (1-549) (VH (MUS MUSCULUS IGHV1-81*01 (89.7%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT (8.8.14) (26-33.51-58.97-110)) (1-121) -HOMO SAPIENS IGHE*01 (100%) (CH1 (122-224), CH2 (225-331), CH3 (332-439), CH4 (440-547), CHS (548-549)) (122-549)), (135-214')-DISULFIDE WITH L-KAPPA LIGHT CHAIN CHIMERIC (1'-214') (V-KAPPA (MUS MUSCULUS IGKV10-96*02 (93.7%) -IGKJ1*01 (100%), CDR-IMGT (6.3.9) (27'-32'.50'-52'.89'-97')) (1'-107') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')); DIMER (242-330'':242''-330)-BISDISULFIDE, PRODUCED IN SP2/0-AG14 MURINE MYELOMA CELL LINE, GLYCOFORM ALFA

IMMUNOGLOBULIN E-KAPPA, ANTI-(HOMO SAPIENS FOLR1 (FOLATE RECEPTOR 1, FOLATE RECEPTOR ALPHA, FR-ALPHA, ADULT FOLATE-BINDING PROTEIN, FBP, OVARIAN TUMOR-ASSOCIATED ANTIGEN MOV18)), CHIMERIC MONOCLONAL ANTIBODY (LAZATATUG)

IMMUNOGLOBULIN G, ANTI-(HUMAN FOLATE RECEPTOR .ALPHA.) (HUMAN-MUS MUSCULUS MONOCLONAL MOV18 .GAMMA.-CHAIN VH REGION) FUSION PROTEIN WITH IMMUNOGLOBULIN E (HUMAN .EPSILON.-CHAIN C REGION), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MOV18 .KAPPA.-CHAIN, DIMER

LAZATATUG [INN]

External Clinical & Regulatory Resources

Previous UNII2D3769I860

Next UNII2D3DP73PWF